Image source: Diplomat Pharmacy, Inc.
Continue Reading Below
After reporting that itspresident and chief financial officer are leaving the company at the end of 2016, shares of Diplomat Pharmacy (NYSE: DPLO)are tumbling 13.6% as of 1:15 p.m EDT.
The specialty pharmacy company has announced that President Gary Kadlec is retiring in December, and that he'll be replaced by company executive Paul Urick in November. Diplomat Pharmacy also says that Sean Whelan, its CFO, will be gone as of Dec. 31.
The C-suite shake-up ahead of the company's approaching third-quarter earnings release next week has investors wondering if there's more to the story. Unfortunately, the company's press release announcing these moves offers up little insight into the timing of their departure.
Continue Reading Below
Investors should get more insight into the reasons behind these changes during the company's third-quarter earnings conference call on Nov. 2. In the meantime, investors may want to keep in mind that Kadlec isn't disappearing altogether. He plans to remain on as a member of the company's board of directors through the rest of his term. It also shouldn't be too surprising that Kadlec is retiring after a 45-year career.
It may also be reassuring to know that Urick is far from a rookie, too. He's beenDiplomat's senior vice president of industry relations, pharmaceutical account management, and payer strategy, and prior to joining Diplomat, he was a senior vice president at Cigna.
Further,Whelan'sexit as chief financial officer isn't immediate, and there's little reason to think that the reason given for his leaving "to spend more time with his family" isn't accurate. It's also good news to hear that Whelan will be involved in transitioning his responsibilities to others.
Overall, while it's disappointing that two senior executives are leaving at the same time, and that there could be some short-term headaches tied to this transition, investors might want to focus more on the long-term opportunity that's ahead for this company. Since development of complex biologics and biosimilars is at record highs, and that means that there's a big opportunity to manage prescriptions for an increasingly larger and longer-living population, stepping in and buying shares for long-haul portfolios might be a good idea.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
Todd Campbell has no position in any stocks mentioned.Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.Like this article? Follow him onTwitter where he goes by the handle@ebcapitalto see more articles like this.
The Motley Fool recommends Diplomat Pharmacy. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.